Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium chloride 0.9% is an isotonic solution that expands extracellular fluid volume, replacing sodium and chloride deficits. Sodium is the primary cation maintaining osmotic pressure and acid-base balance; chloride is the major extracellular anion. The solution provides electrolyte replacement and hydration without altering serum osmolality.
Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.
Fluid and electrolyte replacement in patients with hypovolemia or hyponatremia,Maintenance of intravenous lines,Diluent for compatible medications,Treatment of metabolic alkalosis
Treatment of acute bronchospasm in asthma and COPD,Reversal of dipyridamole-induced adverse effects during stress testing,Apnea of prematurity (off-label),Status asthmaticus (off-label)
Intravenous, 100-200 m L/hour for maintenance; up to 1000 m L bolus for volume resuscitation in adults.
Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.
Not applicable; sodium and chloride ions are endogenous substances with no defined terminal elimination half-life. Excretion half-life is dependent on renal function, typically 6-12 hours in individuals with normal kidney function.
Terminal elimination half-life is 6-12 hours in adults, 1-5 hours in children (due to faster clearance), 20-30 hours in premature neonates, and 10-15 hours in patients with hepatic cirrhosis or heart failure. Clinical context: dosing interval adjustment required based on half-life; prolonged half-life in hepatic impairment or cardiac decompensation increases risk of toxicity.
Sodium and chloride are not metabolized; they are excreted primarily by the kidneys with small amounts lost in sweat and feces.
Hepatic via cytochrome P450 enzymes (CYP1A2, CYP3A4, CYP2E1); saturable kinetics; extensive first-pass metabolism.
Renal: >95% of administered sodium and chloride ions are excreted unchanged in urine; fecal and biliary elimination are negligible (<1%).
Renal excretion of unchanged theophylline (10-20%) and metabolites (80-90%). In neonates, renal excretion of unchanged drug is higher (up to 50%). Biliary/fecal excretion is negligible.
Negligible (<1%); sodium and chloride ions are not significantly bound to plasma proteins.
Approximately 40% bound to plasma proteins, mainly albumin. In neonates, preterm infants, and patients with hepatic cirrhosis, protein binding is reduced (free fraction increases). Binding is also saturable at high theophylline concentrations.
Approximately 0.5-0.7 L/kg (sodium distributes primarily in extracellular fluid; chloride distributes similarly reflecting extracellular space).
Volume of distribution is approximately 0.45 L/kg (range 0.3-0.7 L/kg) in adults. In neonates, Vd is larger (~0.6-0.8 L/kg). Clinical meaning: Vd indicates extensive distribution into body water; loading doses are calculated using Vd (e.g., 1 mg/kg raises serum concentration by ~2 mcg/m L).
Intravenous: 100% (bioavailability not applicable via other routes; oral administration not used for therapeutic effect, and bioavailability is incomplete due to gastrointestinal regulation).
Oral immediate-release: 100% (well absorbed). Rectal: 80-100% (absorption may be erratic). IV: 100%. No significant first-pass metabolism.
Use with caution in renal impairment; monitor fluid and electrolyte balance. No specific dose adjustment required; adjust volume as needed based on urine output and fluid status.
No specific dose adjustment required for GFR >10 m L/min. For GFR <10 m L/min, reduce infusion rate by 50%.
No specific dose adjustment required. Monitor for fluid overload in cirrhosis with ascites.
Child-Pugh Class A: reduce dose by 25%; Class B: reduce dose by 50%; Class C: reduce dose by 75%.
Intravenous, maintenance: 100 m L/kg/day for first 10 kg, then 50 m L/kg/day for next 10 kg, then 20 m L/kg/day for remaining kg. Bolus for hypovolemia: 20 m L/kg.
Loading dose: 5-6 mg/kg IV over 20-30 minutes; continuous infusion: 0.5-0.7 mg/kg/hour (age-dependent, with lower doses for younger children).
Use with caution due to increased risk of fluid overload and electrolyte disturbances. Lower initial infusion rates recommended, with careful monitoring of cardiovascular and renal function.
Elderly patients may have reduced clearance; consider starting at the lower end of dosing range (e.g., 0.3-0.5 mg/kg/hour) and titrate based on serum levels.
None
Theophylline toxicity is dose-related and can be fatal; monitor serum theophylline levels closely; use with caution in patients with risk factors for reduced clearance (e.g., hepatic impairment, heart failure, elderly).
May cause fluid overload, especially in patients with heart failure, renal impairment, or hepatic cirrhosis,Risk of hypernatremia with excessive administration,Monitor serum electrolytes, fluid balance, and renal function during prolonged therapy,Use with caution in patients with hypertension, congestive heart failure, or edema
Narrow therapeutic index; severe toxicity can occur at levels >20 mcg/m L,Seizures and arrhythmias may occur without preceding symptoms,Variable clearance due to drug interactions, disease states, age, and smoking,Use with caution in peptic ulcer disease, seizure disorders, hyperthyroidism, and cardiac disease
Hypernatremia,Fluid overload states (e.g., pulmonary edema, decompensated heart failure),Severe renal impairment with oliguria or anuria
Hypersensitivity to aminophylline or any component,Hypersensitivity to theophylline or ethylenediamine,Cardiac arrhythmias requiring immediate therapy (relative)
No specific food interactions. However, patients on a sodium-restricted diet should be informed about the sodium content (154 m Eq/L). Monitor total daily sodium intake from all sources.
Avoid high-dose caffeine (coffee, tea, energy drinks, chocolate) as it may increase risk of side effects like nausea, anxiety, and tachycardia. Charcoal-broiled foods and a high-protein diet may increase theophylline clearance. Consistent dietary intake is recommended.
Sodium chloride 0.9% is a physiologic saline solution. No teratogenic effects are expected at standard therapeutic doses. Administration during any trimester is considered safe when clinically indicated, as sodium and chloride are normal body constituents. There are no known fetal risks associated with appropriate use.
First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high maternal doses; may cause transient neonatal tachycardia with chronic use. No documented teratogenicity.
Sodium chloride 0.9% is considered compatible with breastfeeding. Sodium and chloride are normal components of breast milk, and intravenous administration does not significantly alter milk composition. No M/P ratio is available as it is a physiologic salt solution.
Aminophylline/theophylline is excreted into breast milk with an M/P ratio of approximately 0.6-0.7. Infant exposure is low (about 1-10% of maternal dose). Irritability and insomnia reported rarely. Use with caution, monitor infant for signs of theophylline toxicity.
No dose adjustment is typically required. Physiological changes in pregnancy (e.g., increased plasma volume) do not necessitate modification of administration rates for isotonic saline, provided standard clinical monitoring is maintained.
Pregnancy decreases theophylline clearance by approximately 20-30% during third trimester. Dosing adjustments may be required: monitor serum levels and adjust dose to maintain therapeutic levels. Postpartum clearance returns rapidly, requiring downward dose adjustment.
0.9% sodium chloride is isotonic and is the preferred crystalloid for volume resuscitation in hemorrhagic shock and for administration of packed red blood cells. Avoid in patients with hypernatremia, fluid overload, or significant renal impairment. Use with caution in congestive heart failure and severe edema. It is compatible with most IV drugs but check compatibility before co-administration.
Aminophylline is a bronchodilator that releases theophylline. Monitor serum theophylline levels (therapeutic range 5-15 mcg/m L). Avoid in patients with active peptic ulcer disease, seizure disorders, or hypersensitivity to xanthines. Caution in hepatic impairment, heart failure, and elderly due to reduced clearance. Drug interactions with cimetidine, ciprofloxacin, and macrolides increase theophylline levels.
This solution replaces fluids and salt in your body and is given through a vein.,Tell your doctor if you have heart failure, kidney problems, or high blood pressure.,You may experience swelling if you receive too much fluid.,Report any shortness of breath, chest pain, or unusual weight gain.
Do not exceed prescribed dose. Take exactly as directed.,Avoid caffeine-containing products (coffee, tea, cola, chocolate) as they may increase side effects.,Report symptoms of toxicity: nausea, vomiting, insomnia, rapid heart rate, palpitations, or seizures.,Do not crush or chew extended-release forms; take with food if gastric upset occurs.,Do not stop abruptly without consulting your healthcare provider.
"Lithium cation may increase the excretion rate of Sodium chloride which could result in a lower serum level and potentially a reduction in efficacy."
"The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan."
"Concurrent administration of aminophylline, a xanthine derivative bronchodilator that is metabolized primarily by CYP1A2 and to a lesser extent CYP3A4, may reduce the clearance of ranolazine, an antianginal agent predominantly metabolized by CYP3A4 and to a lesser extent CYP2D6. Aminophylline can inhibit CYP3A4 activity, leading to increased ranolazine plasma concentrations, which elevates the risk of dose-dependent adverse effects such as QTc prolongation, dizziness, and syncope. This interaction is clinically significant and may necessitate dose adjustment or alternative therapy."
"Asunaprevir, a potent inhibitor of the drug transporter OATP1B1, can significantly decrease the serum concentration of aminophylline, a theophylline salt, likely by reducing its intestinal absorption or increasing its hepatic clearance. This interaction may lead to reduced therapeutic efficacy of aminophylline, potentially worsening respiratory symptoms in patients with asthma or COPD. Close monitoring and dose adjustment of aminophylline are recommended during coadministration with asunaprevir."
"Aminophylline, a bronchodilator, inhibits the metabolism of tibolone, a synthetic steroid hormone used for hormone replacement therapy, primarily through competitive inhibition of cytochrome P450 (CYP) 3A4 isoenzyme. This results in increased plasma concentrations of tibolone and its active metabolites, potentiating its hormonal effects and increasing the risk of adverse events such as thromboembolism, endometrial hyperplasia, or breast tenderness. Clinically, coadministration may require dose adjustments and careful monitoring for signs of estrogenic excess."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER vs AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%, answered by our medical review team.
SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is a Electrolyte that works by Sodium chloride 0.9% is an isotonic solution that expands extracellular fluid volume, replacing sodium and chloride deficits. Sodium is the primary cation maintaining osmotic pressure and acid-base balance; chloride is the major extracellular anion. The solution provides electrolyte replacement and hydration without altering serum osmolality.. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is a Electrolyte that works by Aminophylline is a complex of theophylline and ethylenediamine, acting as a phosphodiesterase inhibitor, increasing intracellular c AMP levels; nonselective adenosine receptor antagonist; enhances cardiac inotropy, bronchodilation, and CNS stimulation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% depend on the specific clinical indication. These are both Electrolyte agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is: Intravenous, 100-200 m L/hour for maintenance; up to 1000 m L bolus for volume resuscitation in adults.. The standard adult dose of AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is: Loading dose: 5-6 mg/kg IV over 20-30 minutes, then continuous infusion: 0.5-0.7 mg/kg/hour IV.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER and AMINOPHYLLINE IN SODIUM CHLORIDE 0.45%. The risk or severity of adverse effects can be increased when Sodium chloride is combined with Tolvaptan. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. SODIUM CHLORIDE 0.9% IN PLASTIC CONTAINER is classified as Category A/B. Sodium chloride 0.9% is a physiologic saline solution. No teratogenic effects are expected at standard therapeutic doses. Administration during any trimester is considered safe whe. AMINOPHYLLINE IN SODIUM CHLORIDE 0.45% is classified as Category A/B. First trimester: Limited data; no increased risk of major malformations observed in human studies. Second and third trimesters: Risk of fetal tachycardia and jitteriness with high . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.